NCT04934579View on ClinicalTrials.gov

Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

October 15, 2022

Study Completion Date

November 15, 2022

Conditions
Primary Central Nervous System Lymphoma
Interventions
DRUG

Rituximab

375mg/m2 intravenous infusion d1, every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 375mg/m2 intravenous infusion d1, every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

DRUG

Lenalidomide

25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.

DRUG

Methotrexate

3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle, 6 cycles will be prescribed.

Trial Locations (1)

310009

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT04934579 - Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | Biotech Hunter | Biotech Hunter